Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer is quietly reshaping its pipeline with a mix of low‑risk formulation upgrades and a few high‑stakes bets, moves that could influence how investors view the stock’s durability beyond COVID revenues. In oncology, the company is running a large post‑marketing observational study in Japan, comparing its Bevacizumab biosimilar with Roche’s Avastin in colorectal cancer to confirm real‑world safety, a key factor for defending share in a price‑sensitive biosimilar market.
At the same time, Pfizer has terminated a Phase 1 trial of its oral KRAS inhibitor PF‑07985045 for advanced solid tumors, a setback that trims one higher‑risk cancer option but mainly impacts pipeline mix rather than the broader investment case. Offsetting that disappointment, Pfizer’s Phase 3 trial of VLA15, a Lyme disease vaccine with partner Valneva, has reached completion, setting the stage for closely watched efficacy data and potential U.S. and European filings that could add a new seasonal revenue stream.
Pfizer is also leaning into lifecycle management on existing assets, including a Phase 1 bioequivalence study of a new orally disintegrating tafamidis tablet versus the current 61 mg capsule, aimed at more convenient dosing in cardiomyopathy patients and modestly extending the franchise. In migraine, another Phase 1 crossover trial is planned to test the bioequivalence of two CGRP receptor antagonist tablets, a small but targeted move to broaden dosing options and keep pace in a competitive field dominated by AbbVie and Eli Lilly.
Taken together, these updates show Pfizer balancing incremental, lower‑risk formulation work with a few larger potential catalysts, particularly the Lyme vaccine readout, which could become a notable driver for sentiment if data are strong. Investors tracking PFE will be watching for safety outcomes from the Bevacizumab biosimilar study, regulatory milestones for VLA15, and any further restructuring of the oncology pipeline as management reallocates capital toward programs with clearer commercial payoffs.